StockNews.AI
NVO
StockNews.AI
195 days

Novo Nordisk's sales increased by 25% in Danish kroner and by 26% at constant exchange rates to DKK 290.4 billion in 2024

1. Novo Nordisk's operating profit surged 25% in 2024. 2. Diabetes and obesity care sales rose 26%, driven mainly by GLP-1 treatments. 3. R&D showed promising results with CagriSema achieving significant weight loss. 4. Sales growth for 2025 is forecasted at 16-24% at constant exchange rates. 5. Dividend for 2024 will increase by 21% to DKK 11.40 per share.

7m saved
Insight
Article

FAQ

Why Bullish?

Strong sales growth and successful R&D typically boost stock prices. Past examples show market appreciation following positive earnings reports.

How important is it?

The financial report's positive metrics indicate strong future potential, directly influencing NVO's outlook.

Why Long Term?

Sustained growth in sales and successful drug developments positively affect investor sentiment over time.

Related Companies

NVOCATG
Bagsværd, 5 February 2025 - Financial report for the period 1 January 2024 to 31 December 2024                                                                                                                                                                         Operating profit increased by 25% in Danish kroner and by 26% at constant exchange rates (CER) to DKK 128.3 billion. Operating profit was positively impacted by gross-to-net sales adjustments in the US and negatively impacted by impairment losses.Sales in North America Operations increased by 30% in Danish kroner (30% at CER). Sales in International Operations increased by 17% in Danish kroner (19% at CER).Sales within Diabetes and Obesity care increased by 26% in Danish kroner to DKK 271.8 billion (27% at CER), mainly driven by GLP-1 diabetes sales growth of 21% in Danish kroner (22% at CER) and Obesity care growing by 56% in Danish kroner to DKK 65.1 billion (57% at CER). Rare disease sales increased by 9% in both Danish kroner and at CER.Within R&D, CagriSema demonstrated superior weight loss in adults with obesity or overweight in the REDEFINE 1 trial, where people treated with CagriSema achieved a superior weight loss of 22.7%. Further, semaglutide 7.2 mg achieved 20.7% weight loss in the STEP UP obesity trial. Lastly, a phase 1b/2a with injectable amycretin in people with overweight or obesity was successfully completed.In December 2024, Novo Nordisk announced that the acquisition of Catalent by Novo Holdings and the related acquisition by Novo Nordisk of three manufacturing sites from Novo Holdings was completed.For the 2025 outlook, sales growth is expected to be 16-24% at CER, and operating profit growth is expected to be 19-27% at CER. Sales and operating profit growth reported in Danish kroner is expected to be 3 and 5 percentage points higher than at CER, respectively.At the Annual General Meeting on 27 March 2025, the Board of Directors will propose a final dividend of DKK 7.90 for 2024 per share. The expected total dividend for 2024 will increase 21% to DKK 11.40 per share, of which DKK 3.50 was paid as interim dividend in August 2024.  PROFIT AND LOSS20242023Growthas reportedGrowthat CER*DKK million    Net sales        290,403                232,261                25%        26%        Operating profit        128,339                102,574                25%        26%             Net profit        100,988                83,683                21%        N/ADiluted earnings per share (in DKK)        22.63                18.62                22%        N/A* CER: Constant exchange rates (average 2023).     Lars Fruergaard Jørgensen, president and CEO: "We are pleased with the performance in 2024, where 26% sales growth reflects that more than 45 million people are now benefiting from our treatments. Further, we completed the acquisition of the three Catalent sites, and during the year, we progressed our R&D pipeline, including obesity projects such as CagriSema and amycretin. In 2025, we will continue our focus on commercial execution, on the progression of our early and late-stage R&D pipeline and on the expansion of our production capacity." On 5 February 2025 at 13.00 CET, corresponding to 07.00 am EST, an earnings call will be held. Investors will be able to listen in via a link on novonordisk.com, which can be found under 'Investors' (the contents of the company's website do not form a part of this Form 6-K). About Novo Nordisk Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 76,300 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, X, LinkedIn and YouTube. Financial Calendar  27 March 2025Annual General meeting 7 May 2025Financial results for the first three months of 2025 6 August 2025Financial results for the first six months of 2025 5 November 2025Financial results for the first nine months of 2025     Novo Nordisk’s Annual Report 2024 is available at https://www.novonordisk.com/investors/annual-report.html and attached in iXBRL format. Contacts for further information Media: Ambre James-Brown+45 3079 9289abmo@novonordisk.comLiz Skrbkova (US)+1 609 917 0632lzsk@novonordisk.com   Investors: Jacob Martin Wiborg Rode+45 3075 5956jrde@novonordisk.comSina Meyer+45 3079 6656azey@novonordisk.comIda Schaap Melvold+45 3077 5649idmg@novonordisk.comFrederik Taylor Pitter (US)+1 609 613 0568fptr@novonordisk.comMax Ung+45 3077 6414mxun@novonordisk.com  Company announcement No 7 / 2025 CA250205-full-year-2024 NOVO-2024-12-31-0-en

Related News